Terms: = Ovarian cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
137 results:
1. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of Immune Infiltrates in ovarian Endometriosis and Endometriosis-Associated ovarian cancer: Relationship with Histological and Clinical Features.
Spagnolo E; Martinez A; Mascarós-Martínez A; Marí-Alexandre J; Carbonell M; González-Cantó E; Pena-Burgos EM; Mc Cormack BA; Tomás-Pérez S; Gilabert-Estellés J; López-Carrasco A; Hidalgo P; Ángeles MA; Redondo A; Gallego A; Hernández A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569458
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced ovarian cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract] [Full Text] [Related]
5. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.
Bartl T; Alberts A; Papadopoulos SC; Wolf A; Muellauer L; Hofstetter G; Grimm C; Cacsire Castillo-Tong D
Int J Gynecol Cancer; 2023 Sep; 33(9):1419-1426. PubMed ID: 37094966
[TBL] [Abstract] [Full Text] [Related]
6. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract] [Full Text] [Related]
7. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
Jlassi A; Manai M; Morjen M; Sahraoui G; Elasmi Allal M; ELBini-Dhouib I; Naija L; Charfi L; Rejaibi R; Ben Ahmed M; Marrakchi N; Srairi-Abid N; Mezlini A; Manai M; Mrad K; Doghri R
PLoS One; 2023; 18(3):e0278849. PubMed ID: 36952478
[TBL] [Abstract] [Full Text] [Related]
8. Circulating CD4
Li R; Xu J; Wu M; Liu S; Fu X; Shang W; Wang T; Jia X; Wang F
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837407
[No Abstract] [Full Text] [Related]
9. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
10. Profiling the immune landscape in mucinous ovarian carcinoma.
Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido Dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ
Gynecol Oncol; 2023 Jan; 168():23-31. PubMed ID: 36368129
[TBL] [Abstract] [Full Text] [Related]
11. VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Buchynska LG; Iurchenko NP; Nesina IP; Glushchenko NM
Exp Oncol; 2022 Nov; 44(3):234-238. PubMed ID: 36325701
[TBL] [Abstract] [Full Text] [Related]
12. cancer co-opts differentiation of B-cell precursors into macrophage-like cells.
Chen C; Park B; Ragonnaud E; Bodogai M; Wang X; Zong L; Lee JM; Beerman I; Biragyn A
Nat Commun; 2022 Sep; 13(1):5376. PubMed ID: 36104343
[TBL] [Abstract] [Full Text] [Related]
13. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
[TBL] [Abstract] [Full Text] [Related]
14. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.
Marchenko S; Piwonski I; Hoffmann I; Sinn BV; Kunze CA; Monjé N; Pohl J; Kulbe H; Schmitt WD; Darb-Esfahani S; Braicu EI; von Brünneck AC; Sehouli J; Denkert C; Horst D; Jöhrens K; Taube ET
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2523-2536. PubMed ID: 35763108
[TBL] [Abstract] [Full Text] [Related]
16. The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.
Matsuura H; Miyamoto M; Hada T; Ishibashi H; Iwahashi H; Kakimoto S; Suzuki R; Ito T; Suminokura J; Tsuda H; Takano M
Arch Gynecol Obstet; 2022 Dec; 306(6):2133-2142. PubMed ID: 35507079
[TBL] [Abstract] [Full Text] [Related]
17. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
[TBL] [Abstract] [Full Text] [Related]
18. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous ovarian Carcinoma.
Peres LC; Colin-Leitzinger C; Sinha S; Marks JR; Conejo-Garcia JR; Alberg AJ; Bandera EV; Berchuck A; Bondy ML; Christensen BC; Cote ML; Doherty JA; Moorman PG; Peters ES; Moran Segura C; Nguyen JV; Schwartz AG; Terry PD; Wilson CM; Fridley BL; Schildkraut JM
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1006-1016. PubMed ID: 35244678
[TBL] [Abstract] [Full Text] [Related]
19. Tumor immune cell clustering and its association with survival in African American women with ovarian cancer.
Wilson C; Soupir AC; Thapa R; Creed J; Nguyen J; Segura CM; Gerke T; Schildkraut JM; Peres LC; Fridley BL
PLoS Comput Biol; 2022 Mar; 18(3):e1009900. PubMed ID: 35235563
[TBL] [Abstract] [Full Text] [Related]
20.
Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
[TBL] [Abstract] [Full Text] [Related]
[Next]
